Geron Drug Fails Breast Cancer Trial, Shares Sink

Cancer drugmaker Geron said it would halt the study of its experimental drug, imetelstat, as a treatment for breast cancer and the drug was also unlikely to move forward in trials for advanced non-small cell lung cancer, causing the company’s shares to shed nearly half their value.
Medcity News